NVTA - NVTA インビティ ()

NVTAのニュース

   Cathie Wood called this one of her most underappreciated stocks. Its CEO explains its growth story  2021/03/13 00:10:46 CNBC
Invitae CEO Sean George told CNBC he believes genetic testing will be central to health-care decisions in five to 10 years.
   Invitae Releases Inaugural Environmental, Social and Governance (ESG) Report  2021/03/11 12:30:00 PR Newswire
SAN FRANCISCO, March 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the issuance of its inaugural Environmental, Social and Governance (ESG) report, augmenting the company's disclosures regarding its ESG strategy and…
   Global Clinical Next-Generation Sequencing (NGS) Market Report 2021 Featuring ArcherDx, AstraZeneca, BioNTech, Exact Sciences, Grail, Illumina, Invitae, Moderna, Pfizer & Thrive Earlier Detection  2021/03/10 16:15:00 PR Newswire
DUBLIN, March 10, 2021 /PRNewswire/ -- The "Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-Generation Sequencing (NGS) Market" report has been added to ResearchAndMarkets.com's offering. 2020 will be remembered for the COVID-19 pandemic, masks, social distancing…
   Invitae Co. (NYSE:NVTA) CEO Sells $134,762.25 in Stock  2021/03/06 12:48:45 Watchlist News
Invitae Co. (NYSE:NVTA) CEO Sean E. George sold 3,675 shares of the business’s stock in a transaction dated Thursday, March 4th. The shares were sold at an average price of $36.67, for a total value of $134,762.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the […]
   Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference  2021/03/04 12:30:00 PR Newswire
SAN FRANCISCO, March 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern / 7:40…
   Invitae to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021  2021/02/03 12:30:00 PR Newswire
SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2020 financial results on Wednesday, February 17, 2021 and will host a conference call and webcast that…
   Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program  2021/01/29 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a partnership with Invitae, a leading medical genetics company, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy. “We are pleased to collaborate with Invitae to introduce Am
   Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering  2021/01/26 21:05:00 PR Newswire
SAN FRANCISCO, Jan. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sold pursuant to the exercise in full of the underwriters' option to purchase…
   Invitae Announces Pricing of Public Offering of Common Stock  2021/01/22 01:37:00 PR Newswire
SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross…
   Invitae Announces Proposed Public Offering of Common Stock  2021/01/20 21:05:00 PR Newswire
SAN FRANCISCO, Jan. 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of…
   Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program  2021/01/29 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a partnership with Invitae, a leading medical genetics company, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy. “We are pleased to collaborate with Invitae to introduce Am
   Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering  2021/01/26 21:05:00 PR Newswire
SAN FRANCISCO, Jan. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sold pursuant to the exercise in full of the underwriters' option to purchase…
   Invitae Announces Pricing of Public Offering of Common Stock  2021/01/22 01:37:00 PR Newswire
SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross…
   Invitae Announces Proposed Public Offering of Common Stock  2021/01/20 21:05:00 PR Newswire
SAN FRANCISCO, Jan. 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of…
   Leerink Partners Stick to Their Buy Rating for Invitae By Investing.com  2021/01/20 12:45:52 Investing.com
Leerink Partners Stick to Their Buy Rating for Invitae

calendar